News

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include:  What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our …

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast Read More »

MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma …

December, 2019: BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza” Read More »

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based …

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »

MORRISTOWN, NJ, (August 22, 2019) BioAegis Therapeutics, Inc., a clinical stage company developing technology to control inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of research results in the Journal of Infectious Diseases demonstrating that recombinant human plasma gelsolin therapy dramatically improves survival in a multidrug-resistant …

August, 2019: BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia” Read More »

MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring hospitalization because of Community-Acquired Pneumonia. This blinded placebo-controlled trial was a dose-escalation study with four cohorts of 8 patients randomized 3:1 to recombinant gelsolin versus placebo. The …

August, 2019: BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients Read More »

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 30, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing recombinant human plasma gelsolin (pGSN) announced today that the United States Patent Office has issued a patent for the Use of Plasma Gelsolin to Diagnose and Treat Renal Failure. Read the full press release here: Renal Patent 2019

MORRISTOWN, NJ (March 18, 2019). BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients requiring hospitalization because of Community-Acquired Pneumonia (CAP). A Novel Approach to Create a New Treatment Paradigm Severe CAP is the lead indication of this clinical-stage …

March 2019: BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia Read More »

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) March 13, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection announced today that the European Patent Office has issued …

March, 2019: BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections Read More »

MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in the Republic of Georgia. The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around the supplementation of …

February 2019: BioAegis Therapeutics Expands Phase 1b/2a Community- Acquired Pneumonia Study to the Republic of Georgia — Successfully Completes Second of Four Dosing Cohorts Read More »